drugset / Trial / NCT05735158
Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
RandomizedParallel-groupTriple-blindTreatment
Summary
KB105-02 is an intrasubject randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KB105 in children and adults with autosomal recessive congenital ichthyosis (ARCI).
Timeline
- Start
- 2023-03
- Primary completion
- 2024-03
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INETAGUGENE GEPERPAVEC | Unknown | — | Topical |